Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
Prysmian Nears Deal to Acquire Atkore in Potential All-Cash Takeover 
Meta Cuts Wipro Outsourcing by 25% After AI-Led Restructuring 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Capital One Says AML Review Led to Closure of Trump Organization Accounts 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
BYD July Global Vehicle Sales Rise 22% as Overseas Demand Surges 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
World game at war: why some European nations have threatened a World Cup boycott 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
NEW YORK, April 16, 2018 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Celgene Corporation ("Celgene") (NASDAQ:CELG) between September 12, 2016 and February 27, 2018. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of New Jersey. To get more information go to:
http://www.zlk.com/pslra-d/celgene-corporation?wire=3
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) the trials for GED-0301 suffered from fatal design defects, such that GED-0301 had failed to demonstrate meaningful clinical efficacy; (3) the growth of Otezla sales had dramatically slowed during Celgene's third fiscal quarter of 2017; and (4) the clinical and nonclinical pharmacology data in Celgene's new drug application ("NDA") for Ozanimod were insufficient to permit a complete review by the FDA, which resulted in the FDA issuing a refusal to file letter to Celgene regarding the NDA.
If you suffered a loss in Celgene you have until May 29, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com
